The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 15 04 2021
revised: 12 08 2021
accepted: 18 08 2021
medline: 24 11 2023
pubmed: 10 9 2023
entrez: 9 9 2023
Statut: ppublish

Résumé

A TNM-based system for all types of thymic epithelial tumors was introduced in the eighth edition of the TNM classification of thoracic malignancies. The Thymic Domain of the Staging and Prognostic Factors Committee of the International Association for the Study of Lung Cancer, composed of multispecialty international experts, was charged to develop proposals for the ninth edition. This article outlines the proposed definitions for the T, the N, and the M components and their combination into stage groups. A large central database of 11,347 patients with thymic epithelial tumors was assembled thanks to the contribution of the major thymic organizations worldwide and analyses were carried out for the T, the N, and the M components and the stage groups. Overall survival was the outcome measure for patients with completely and incompletely resected tumors, and recurrence for those with complete resection. When the number of patients was sufficient, analyses were performed separately for thymomas, thymic carcinomas, and neuroendocrine thymic tumors. Tumor size is included in the T1 category as T1a (≤5cm) and T1b (>5 cm); the mediastinal pleura is dropped as a T descriptor; invasion of the lung or phrenic nerve is reclassified as T2 (instead of T3). No changes are proposed for the N and the M components from the eighth edition. The stage groups remain the same. The proposed changes for the ninth edition of the TNM classification set the stage for further progress in the future for these rare tumors.

Identifiants

pubmed: 37689391
pii: S1556-0864(23)00804-3
doi: 10.1016/j.jtho.2023.09.002
pii:
doi:

Substances chimiques

Myeloma Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1655-1671

Informations de copyright

Copyright © 2023 International Association for the Study of Lung Cancer. All rights reserved.

Auteurs

Enrico Ruffini (E)

University of Torino, Torino, Italy. Electronic address: enrico.ruffini@unito.it.

James Huang (J)

Memorial Sloan Kettering Cancer Center, New York, New York.

Vanessa Cilento (V)

Cancer Research And Biostatistics (CRAB), Seattle, Washington.

Emily Goren (E)

Cancer Research And Biostatistics (CRAB), Seattle, Washington.

Frank Detterbeck (F)

Yale University School of Medicine, New Haven, Connecticut.

Usman Ahmad (U)

Thoracic Surgery in the Heart, Vascular, and Thoracic Institute at Cleveland Clinic, Abu Dhabi, United Arab Emirates.

Sarit Appel (S)

Sheba Medical Center, Ramat Gan, Israel.

Andrea Bille (A)

Guy's Hospital, London, United Kingdom.

Souheil Boubia (S)

University Hospital Ibn Rochd, Casablanca, Morocco.

Cecilia Brambilla (C)

Royal Brompton and Harefield National Health Service (NHS) Hospitals, London, United Kingdom; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom.

Ayten Kayi Cangir (AK)

Ankara University Faculty of Medicine, Ankara, Turkey.

Conrad Falkson (C)

Queen's University in Kingston, Ontario, Canada.

Wentao Fang (W)

Shanghai Chest Hospital, Jiaotong University Medical School, Shanghai, People's Republic of China.

Pier Luigi Filosso (PL)

Baggiovara Civil Hospital, University of Modena, Italy.

Giuseppe Giaccone (G)

Meyer Cancer Center, Weill-Cornell Medicine, New York, New York.

Nicolas Girard (N)

Institut Curie, Thorax Institute Curie Montsouris, Paris, France; Paris Saclay University, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Versailles, France.

Francesco Guerrera (F)

University of Torino, Torino, Italy.

Maurizio Infante (M)

University and Hospital Trust, Verona, Italy.

Dong Kwan Kim (DK)

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Marco Lucchi (M)

Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

Mirella Marino (M)

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Edith M Marom (EM)

Department of Diagnostic Imaging, Chaim Sheba Medical Center, Tel-Aviv University, Ramat Gan, Israel.

Andrew G Nicholson (AG)

Royal Brompton and Harefield National Health Service (NHS) Hospitals, London, United Kingdom; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom.

Meinoshin Okumura (M)

National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.

Ramon Rami-Porta (R)

Hospital Universitari Mutua Terrassa, Terrassa, Spain; Network of Centers for Biomedical Research in Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Spain.

Andreas Rimner (A)

Memorial Sloan Kettering Cancer Center, New York, New York.

Charles B Simone (CB)

Memorial Sloan Kettering Cancer Center, New York, New York.

Hisao Asamura (H)

Keio University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH